Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Augmedix Q4 2023 GAAP EPS $(0.09) Beats $(0.10) Estimate, Sales $12.680M Beat $12.466M Estimate

Author: Benzinga Newsdesk | March 18, 2024 04:05pm
Augmedix (NASDAQ:AUGX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. The company reported quarterly sales of $12.680 million which beat the analyst consensus estimate of $12.466 million by 1.72 percent. This is a 44.90 percent increase over sales of $8.751 million the same period last year.

Posted In: AUGX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist